抗CGRP单克隆抗体,偏头痛和情绪障碍:一项观察性研究
Marco Bolchini1,2, Giulia Ceccardi3,4, Francesca Schiano di Cola3,4
1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. marco.bolchini1@gmail.com.
概括
抗CGRP抗体有效降低偏头痛症状,并改善并发性焦虑和抑郁症. 这种治疗有益于患者,无论情绪障碍的严重程度如何,显示持续的积极结果.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛经常与焦虑和抑郁障碍同时发生,恶化结果.
- 精神病的并发症可能会使偏头痛管理复杂化,并导致慢性化.
研究的目的:
- 在偏头痛患者中评估抗CGRP抗体的疗效.
- 评估抗CGRP抗体对伴随性焦虑和抑郁症状的影响.
主要方法:
- 对206名偏头痛门诊患者进行了回顾性观察性研究,这些患者接受了抗CGRP抗体的治疗.
- 使用贝克抑郁 inventory (BDI) 和祖格焦虑量表进行评估.
- 对临床结果和情绪症状尺度在3个月和6个月后的分析.
主要成果:
- 观察到每月头痛和偏头痛日数显著减少.
- 偏头痛结果的临床改善在各个患者群体中是一致的,包括那些有情绪障碍的人.
- 反CGRP抗体治疗导致焦虑和抑郁症状显著改善.
结论:
- 抗CGRP抗体治疗对偏头痛患者有效,即使有伴随性情绪症状.
- 该疗法对情绪症状的严重程度和强度表现出持续的有益影响.
- 这种治疗方法对患有偏头痛与精神病相关疾病的患者产生了积极的影响.
相关概念视频
Cholinergic Antagonists: Therapeutic Uses
876
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
876
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
264
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
264
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
405
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
405


